🚀 VC round data is live in beta, check it out!
Regencell Bioscience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Regencell Bioscience and similar public comparables like Yunnan Baiyao Group, Sino Biopharmaceutical, BridgeBio Pharma, Neurocrine Biosciences and more.
Regencell Bioscience Overview
About Regencell Bioscience
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems.
Founded
2014
HQ
Employees
10
Website
Sectors
Financials (FY)
EV
$14B
Regencell Bioscience Financials
Regencell Bioscience reported last fiscal year revenue of — and negative EBITDA of ($3M).
In the same fiscal year, Regencell Bioscience generated ($3M) in EBITDA losses and had net loss of ($4M).
Regencell Bioscience P&L
In the most recent fiscal year, Regencell Bioscience reported revenue of — and EBITDA of ($3M).
Regencell Bioscience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($3M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Regencell Bioscience Stock Performance
Regencell Bioscience has current market cap of $14B, and enterprise value of $14B.
Market Cap Evolution
Regencell Bioscience's stock price is $28.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $14B | $14B | -6.1% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRegencell Bioscience Valuation Multiples
Regencell Bioscience trades at (4196.5x) EV/EBITDA.
Regencell Bioscience Financial Valuation Multiples
As of April 18, 2026, Regencell Bioscience has market cap of $14B and EV of $14B.
Equity research analysts estimate Regencell Bioscience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Regencell Bioscience has a P/E ratio of (3955.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $14B | XXX | $14B | XXX | XXX | XXX |
| EV (current) | $14B | XXX | $14B | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4196.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (3759.3x) | XXX | XXX | XXX |
| P/E | — | XXX | (3955.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4339.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Regencell Bioscience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Regencell Bioscience Margins & Growth Rates
Regencell Bioscience's revenue in the last fiscal year grew by —.
Regencell Bioscience's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
Regencell Bioscience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (8%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Regencell Bioscience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Regencell Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Yunnan Baiyao Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Sino Biopharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| BridgeBio Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Neurocrine Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascendis Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Regencell Bioscience M&A Activity
Regencell Bioscience acquired XXX companies to date.
Last acquisition by Regencell Bioscience was on XXXXXXXX, XXXXX. Regencell Bioscience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Regencell Bioscience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRegencell Bioscience Investment Activity
Regencell Bioscience invested in XXX companies to date.
Regencell Bioscience made its latest investment on XXXXXXXX, XXXXX. Regencell Bioscience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Regencell Bioscience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Regencell Bioscience
| When was Regencell Bioscience founded? | Regencell Bioscience was founded in 2014. |
| Where is Regencell Bioscience headquartered? | Regencell Bioscience is headquartered in Hong Kong. |
| How many employees does Regencell Bioscience have? | As of today, Regencell Bioscience has over 10 employees. |
| Who is the CEO of Regencell Bioscience? | Regencell Bioscience's CEO is Yat-Gai Au. |
| Is Regencell Bioscience publicly listed? | Yes, Regencell Bioscience is a public company listed on Nasdaq. |
| What is the stock symbol of Regencell Bioscience? | Regencell Bioscience trades under RGC ticker. |
| When did Regencell Bioscience go public? | Regencell Bioscience went public in 2021. |
| Who are competitors of Regencell Bioscience? | Regencell Bioscience main competitors are Yunnan Baiyao Group, Sino Biopharmaceutical, BridgeBio Pharma, Neurocrine Biosciences. |
| What is the current market cap of Regencell Bioscience? | Regencell Bioscience's current market cap is $14B. |
| Is Regencell Bioscience profitable? | No, Regencell Bioscience is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.